PMID- 38094010
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231214
IS  - 2589-3610 (Electronic)
IS  - 1674-6384 (Print)
IS  - 1674-6384 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Oct
TI  - Mangiferin alleviates renal inflammatory injury in spontaneously hypertensive 
      rats by inhibiting MCP-1/CCR2 signaling pathway.
PG  - 556-563
LID - 10.1016/j.chmed.2022.12.008 [doi]
AB  - OBJECTIVE: Hypertension is a low-grade inflammation state of the disease and was 
      easily complicated by kidneys' inflammatory response. Mangiferin (MGF), a 
      pharmacologically active compound in various plants including Mangifera indica, 
      has a strong anti-inflammatory activity. However, the effects of MGF on renal 
      inflammatory injury in spontaneously hypertensive rats (SHRs) remain unclear. The 
      purpose of this study was to investigate the protective effects and mechanisms of 
      MGF on renal inflammatory injury in SHRs. METHODS: MGF was used in SHRs at the 
      doses of 10, 20, 40 mg/kg/d for 8 weeks consecutively. The blood and urine were 
      collected for assessment of renal function. Renal tissues were collected for 
      histological, immunohistochemistry, ELISA, Western blot and real time reverse 
      transcription PCR (RT-PCR) analysis. RESULTS: The results showed that the levels 
      of interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), monocyte 
      chemoattractant protein-1 (MCP-1) and recombinant chemokine C-C-Motif receptor 2 
      (CCR2) were increased in SHRs, meanwhile, the level of IL-10 was decreased in 
      SHR. Treatment of MGF inhibited the expression of IL-6, TNF-alpha, MCP-1 and CCR2, 
      and promoted the expression of IL-10. Furthermore, the content of blood urea 
      nitrogen (BUN) and serum uric acid (SUA) was significantly increased in the model 
      group, and treatment of MGF had no obvious effects on these parameters at all 
      dose levels. CONCLUSION: Our study proved that the kidneys of SHRs had 
      significant inflammatory injury, and MGF had the protective effects on renal 
      inflammatory injury in SHRs; The protective mechanism may be mediated partly by 
      the MCP-1/CCR2 signaling pathway. Thus, it is a potential new drug for the 
      treatment of hypertension.
CI  - (c) 2023 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V.
FAU - Hu, Xiaoqin
AU  - Hu X
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
AD  - Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Nanning 
      530001, China.
AD  - Jinhua Advanced Research Institute, Jinhua 321000, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
FAU - Deng, Jiagang
AU  - Deng J
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
AD  - Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Nanning 
      530001, China.
FAU - Du, Zhengcai
AU  - Du Z
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
FAU - Zeng, Xuewen
AU  - Zeng X
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
AD  - Jinhua Advanced Research Institute, Jinhua 321000, China.
FAU - Zhou, Bei
AU  - Zhou B
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
AD  - Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Nanning 
      530001, China.
FAU - Hao, Erwei
AU  - Hao E
AD  - College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530001, 
      China.
AD  - Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Nanning 
      530001, China.
LA  - eng
PT  - Journal Article
DEP - 20230327
PL  - Singapore
TA  - Chin Herb Med
JT  - Chinese herbal medicines
JID - 101556727
PMC - PMC10715884
OTO - NOTNLM
OT  - MCP-1/CCR2
OT  - hypertension
OT  - mangiferin
OT  - renal inflammatory injury
OT  - spontaneously hypertensive rat
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/12/14 06:42
MHDA- 2023/12/14 06:43
PMCR- 2023/03/27
CRDT- 2023/12/14 04:07
PHST- 2022/09/14 00:00 [received]
PHST- 2022/11/16 00:00 [revised]
PHST- 2022/12/10 00:00 [accepted]
PHST- 2023/12/14 06:43 [medline]
PHST- 2023/12/14 06:42 [pubmed]
PHST- 2023/12/14 04:07 [entrez]
PHST- 2023/03/27 00:00 [pmc-release]
AID - S1674-6384(23)00027-8 [pii]
AID - 10.1016/j.chmed.2022.12.008 [doi]
PST - epublish
SO  - Chin Herb Med. 2023 Mar 27;15(4):556-563. doi: 10.1016/j.chmed.2022.12.008. 
      eCollection 2023 Oct.